Bentley's Nasulin to move into Ph II in India

26 February 2007

Bentley Pharmaceuticals, a US specialty pharmaceutical company, has received approval from the Drug Controller General of India to proceed with a Phase II clinical evaluation of its Nasulin in type 2 diabetic patients. Nasulin is the company's intranasal insulin product utilizing its proprietary CPE-215 delivery technology.

This follows the completion of its pharmacokinetic clinical studies of Nasulin studies in India. The 12-week Phase II study will be initiated in March and is expected to be completed before the end of 2007.

John Sedor, president of Bentley commented: "this expansion marks an incremental milestone in the clinical development of our Nasulin. We are encouraged by the progression of data we've accumulated in the insulin program, which further validates our intranasal delivery technology platform and its potential to deliver other therapeutic peptides in similar formulations to insulin."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.